Investigational drug · Phase 3
Human Diploid Cell
Also called: Inactivated Hepatitis A Vaccine, Healive, Experimental Lyophilized Human Rabies Vaccine
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hepatitis A Vaccine, Rabies Prevention.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
67
Any phase or sponsor naming "Human Diploid Cell"
First trial start
2026
Mar 4, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Human Diploid Cell", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatitis A Vaccine
- Rabies Prevention
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Human Diploid Cell" as an intervention, largest first.
- The Phase IVb of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese ChildrenCompleted
Institute of Medical Biology, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT03001986 · 40,724 participants · Start Sep 2016 · Primary completion Dec 2017
Drug: inactivated EV71 vaccine (KMB-17 cells) · For: Hand, Foot and Mouth Disease (HFMD)
Sites: Wuhan, China
Chinese Academy of Medical SciencesAcademic, hospital or other
NCT02999828 · 20,770 participants · Start Sep 2016 · Primary completion Feb 2019
Drug: inactivated EV71 vaccine (KMB-17) · For: Safety of Inactivated EV71 Vaccine; Immunization of Inactivated EV71 Vaccine
Sites: Beijing, China
- A Protected Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants and ChildrenPivotal-lookingCompleted
Institute of Medical Biology, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT01569581 · 12,000 participants · Start Mar 2012 · Primary completion Mar 2013
Drug: 100U/0.5ml in 6-11 months old infants; 100U/0.5ml in 12-23 months old infants and 2 more · For: The Efficacy of Inactivated EV71 Vaccine (KMB17) Against HFMD in Chinese Children and Infants
Sites: Nanning, China
- Phase II/III of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Healthy Children Aged 5-11Pivotal-lookingStatus unknown
Institute of Medical Biology, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT04591405 · 11,999 participants · Start Oct 12, 2020 · Primary completion Jul 1, 2024
Drug: Attenuated Mumps vaccine (KMB-17) in phase II and III; Placebo in phase II and 2 more · For: Epidemic Parotitis, Mumps
Sites: Wuhan, China
- A Clinical Trial of Rabies Vaccine(Human Diploid Cell)for Human Use,Freeze-dried in a Population Aged 10 to 60 YearsPivotal-lookingActive, not recruiting
Ab&B Bio-tech Co., Ltd.JSAcademic, hospital or other
NCT07275645 · 3,000 participants (planned) · Start Feb 26, 2026 · Primary completion Nov 26, 2026
Drug: Rabies Vaccine(Human Diploid Cell)for Human Use,Freeze-dried; Rabies Vaccine(Human Diploid Cell)for Human Use,Freeze-dried and 3 more · For: Rabies
Sites: Huanggang, China; Shiyan, China; Xiangyang, China · 5 sites in all
- Clinical Trial of Freeze-dried Human Rabies Vaccine (Human Diploid Cells)Pivotal-lookingCompleted
Ningbo Rongan Biological Pharmaceutical Co., Ltd.Industry
NCT07028801 · 3,000 participants · Start Jul 30, 2025 · Primary completion Apr 8, 2026
Drug: Freeze-dried human rabies vaccine (human diploid cells); Freeze-dried human rabies vaccine (human diploid cells) and 3 more · For: Rabies
Sites: Zhengzhou, China
- A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)Pivotal-lookingEnrolling by invitation
Changchun BCHT Biotechnology Co.Industry
NCT07500207 · 3,000 participants (planned) · Start Mar 4, 2026 · Primary completion May 25, 2026
Drug: Experimental Lyophilized Human Rabies Vaccine (Human Diploid Cell); approved Rabies vaccine · For: Rabies Prevention
Sites: Neijiang, China
- Study of Concomitant Administration of the sIPV and DTaP or MMRPivotal-lookingNot yet recruiting
Institute of Medical Biology, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT06920069 · 2,640 participants (planned) · Start May 15, 2025 · Primary completion Jul 15, 2030
Drug: sIPV; DTaP and 2 more · For: Polio; Diphteria, Tetanus and Pertussis; MMR Vaccine
Sites: Chuxiong, China; Puer, China; Wenshan, China · 9 sites in all
- Immunogenicity and Safety of A Lyophilized Purified Human Diploid Cell Rabies Vaccine .Pivotal-lookingCompleted
Jiangsu Province Centers for Disease Control and PreventionResearch network
NCT03971370 · 1,800 participants · Start Sep 10, 2017 · Primary completion Sep 29, 2018
Drug: Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd); Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd) and 1 more · For: Adverse Effect and Immunogenicity of Vaccine
Sites: Nanjing, China
- Lot-to-lot Consistency Study of Three Commercial Batches of Enterovirus 71 VaccinePivotal-lookingStatus unknown
Institute of Medical Biology, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT06146088 · 1,500 participants (planned) · Start Nov 25, 2023 · Primary completion Mar 31, 2024
Drug: EV71 Vaccine · For: Hand, Foot and Mouth Disease
Sites: Baoji, China; Hanzhong, China; Weinan, China · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Immunogenicity and safety of inactivated TZ84- vs. HM175-based hepatitis A vaccines in pediatric populations: A systematic review and meta-analysis.
Kundu R, Ghosh A, Toppo A, et al. · Hum Vaccin Immunother 2026
- Pre-clinical immunogenicity and safety evaluation of H2 strain Hepatitis A Inactivated Vaccine in rhesus macaques.
Ping L, Chu H, Li Z, et al. · Antiviral Res 2026
- Establishing humoral immunity to rabies in a person with multiple sclerosis through booster vaccination: A case report.
Dinov D, Hardeman P, Tessier J, et al. · Mult Scler J Exp Transl Clin 2026
- Incremental Effectiveness of a Second Varicella Vaccine in Children: A Prospective Cohort Study in Anhui, China.
Xuan K, Li T, Zha Z, et al. · Vaccines (Basel) 2026
- Protective efficacy of GMAI-02, a cDNA-derived inactivated hepatitis A vaccine, against HM175/mp7 challenge in interferon-receptor-deficient mice.
Chung YJ, Oh HS, Kim SO, et al. · Virology 2026
- Factors influencing rabies vaccines immunogenicity during post-exposure prophylaxis: a systematic literature search and meta-analysis.
Morelli F, Augard C, Bourhy H, et al. · Vaccine 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.